Oc020—Optimal Sampling Strategy For Busulfan In Stem Cell Transplantation Patients  by Castro, F.A. et al.
Clinical Therapeutics
e8 Volume 35 Number 8S
II (liraglutide, saxagliptin), depression (agomelatine), bipolar dis-
order (asenapine), and epilepsy (eslicarbazepine). Data of all Phase 
II and III trials were identified in the European public assessment 
reports, the WHO Trials Registry, and PubMed. Outcome measures: 
the number of randomized subjects and the number of those aged 65 
and 75 years and older. Trials with missing data were not included 
in the calculation of that outcome. Rates of trials giving information 
about the number of older subjects and the proportions of older 
people were calculated.
Results: The number of people aged 65+ and 75+ was available in 
39% and 48% of the 116 included trials, respectively. The propor-
tion of older people varied from 0% to 93%. In trials for indications 
primarily related to aging (n = 7), 47.1% of the subjects were 65+ 
(median, 2681; range, 524–5848); 20.6% were 75+ (median, 1575; 
range, 216–5848). In trials for indications not specific for, but present 
in old age (n = 5), 7.5% of the subjects were 65+ (median, 108; range, 
14–887); 0.9% were aged 75 and older (median, 26; range, 0–83).
Conclusion: This study on the number of older subjects in clinical 
trials of recently authorized drugs shows that in trials for indications 
primarily related to aging, almost half of the randomized subjects are 
aged 65 and older. In trials for indications not specific for, but present 
in old age, the number and especially the proportion of older subjects 
is limited. So, serious improvement concerning the inclusion of the 
older target population is needed for drugs intended for younger as 
well as for older patients.
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Introduction: A single inhaled dose of laninamivir octanoate (LO), 
a long-acting neuraminidase inhibitor, exhibits efficacy to treat both 
adult and pediatric patients with influenza virus infection. However, 
the relation between the intrapulmonary pharmacokinetics (PK) of 
LO and laninamivir, an active metabolite, and its long-lasting efficacy 
has not fully been investigated. Intrapulmonary pharmacokinetics 
in healthy volunteers and the intracellular drug disposition in mice 
were evaluated to clarify the potential mechanism for the prolonged 
high intrapulmonary retention of laninamivir, which would support 
its long-lasting efficacy.
Patients (or Materials) and Methods: A single-center, open-label 
study was performed in adult healthy volunteers. Seven subgroups of 
5 subjects each underwent bronchoalveolar lavage (BAL) at specified 
time intervals from 4 to 240 hours after a single inhaled administra-
tion of LO (40 mg). Plasma, BAL fluid, and alveolar macrophage 
(AM) were analyzed to determine laninamivir and LO concentrations 
using validated LC-MS/MS methods. The concentrations in epithe-
lial lining fluid (ELF) were calculated by the urea diffusion method. 
Microautoradiographic localization in the respiratory tissues was 
evaluated after a single intranasal administration of radiolabeled LO 
to mice. In addition, the disposition of LO and laninamivir was evalu-
ated by measuring the drug uptake and release in primary cultured 
mouse airway epithelial cells.
Results: In healthy volunteers, the peak plasma concentrations of 
laninamivir occurred at 3.5 hours after inhalation and decreased 
with the half-life of 45.7 hours. Laninamivir concentrations in ELF 
and AM were much higher than those in plasma and lasted for 240 
hours. Cmax of laninamivir in ELF from first BAL was 8.6 μ g/mL and 
laninamivir in ELF decreased with longer half-life (~6 days) than that 
in plasma. Laninamivir concentrations in ELF notably exceeded the 
IC50 values for viral neuraminidase at all time points examined. In 
mice, the labeled LO derived activity after an intranasal administra-
tion mainly located on the epithelial cells for a long period. The 
uptake of LO in airway epithelial cells increased without any appar-
ent saturation even at the highest concentration tested (1000 μ M). 
Furthermore, the intracellular laninamivir was released very slowly 
into the drug-free medium, which was regarded as a rate-limiting 
step in the cellular retention.
Conclusion: ELF concentration profiles and prolonged high intrapul-
monary retention of laninamivir support its long-lasting efficacy to 
treat patients with influenza virus infection by the single inhalation.
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Introduction: Busulfan, an alkylating agent, is used in combination 
with other drugs in patients undergoing stem cell transplantation. 
Busulfan presents a very narrow therapeutic window, which has been 
linked to various adverse events. Therapeutic monitoring protocols 
have been developed to allow the individualization of the dose, but 
the dose selection and the sampling time for pharmacokinetics are 
based on empirical evidence. Consequently, target exposure cannot be 
warranted. The aim of this investigation was to determine the optimal 
sampling scheme and develop a model-based dosing algorithm for 
busulfan in stem cell transplantation patients.
Patients (or Materials) and Methods: Clinical data (n = 29) from 
an ongoing study were used for the purposes our analysis. A 1-com-
partment model was selected as basis for sampling optimization and 
subsequent evaluation of a suitable dosing algorithm. Internal and 
external model validation procedures were performed before the opti-
mization steps using ED-optimality criteria. Clearance and volume 
of distribution were considered as parameters of interest. The final 
sampling scheme and dosing algorithm were based on the deviation 
from target exposure range, as determined by AUC(0–6).
Results: A 1-compartment model was found to describe busulfan 
exposure after oral administration, with ideal body weight (IBW) 
and alanine transferase (ALT) as covariates on clearance. A sparse 
sampling scheme with five samples per patient (t = 0.5, 2.25, 3, 4, and 
5 hours after dose) was found to be sufficient for the characterization 
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of busulfan pharmacokinetics. In conjunction with sparse sampling, 
the proposed model-based dosing algorithm appears to ensure that 
patients achieve and maintain the expected target exposure.
Conclusion: In contrast to the current clinical protocol, which relies 
on a linear correlation between dose and body weight, our findings 
reveal the clinical implications of a nonlinear correlation between 
body size, liver function, and drug elimination. The definition of the 
sparse ideal optimal design for busulfan constitutes an important 
improvement in therapeutic drug monitoring routine. Moreover, the 
availability of a model-based dosing algorithm for dose individu-
alization may contribute to considerable improvement in the safety 
and efficacy profile of patients undergoing treatment for stem cell 
transplantation.
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Introduction: In present scenario, India becomes a hub for con-
ducting clinical trials. Hence, need good clinical practice (GCP) to 
conduct a clinical trial. Initiative of Indian government of clinical 
trial registry (CTRI) has helped in increasing transparency, account-
ability, and accessibility of clinical trials. We conducted retrospective 
observational study aimed to establish current Indian status of Good 
Clinical Practice certified clinical investigators in major government 
hospitals, private hospitals, and small polyclinic.
Patients (or Materials) and Methods: We have done extensive search 
of clinical trials registry in India to obtain information regarding the 
total number of trials registered and further divided into the sites 
specific like major government hospitals, private hospitals, and small 
polyclinic from year 2007 to 2012.
Results: Our paper is first of a kind to demonstrate the sites preferred 
by sponsor or investigator for conducting clinical trials. Looking into 
the data, it was found private institutes were preferred compared 
with government institutes and increasing number of trials were also 
conducted in polyclinics. Trends toward allocating of private institute 
though increased by 2011 but by 2012, both government and private 
institutes were equally allocated for clinical trials but decrease in 
registration of trials is noticed by the 2012. Proper coordination and 
timely completion of trial should be aimed at properly trained, quali-
fied, and experienced staff (GCP trained) with standard laboratories 
and regular monitoring.
Conclusion: Present study showed the importance and differences 
of site specific application of GCP objectives. The principle of GCP 
should be followed regardless of site and then expect a good clinical 
outcome and training during the study.
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Introduction: This study (in vivo) was performed to investigate so-
called “drift” with generic–generic drug substitution, namely whether 
a registered generic formulation is also bioequivalent to another 
generic formulation, fulfilling the 80% to 125% criterion.
Patients (or Materials) and Methods: This bioequivalence study was 
conducted at Maastricht University Medical Centre, and designed as 
a 800-mg tablet, single-dose, 4-treatment (Neurontin® and 3 regis-
tered generic gabapentin products), randomized, 4-way crossover 
trial in 24 healthy volunteers under fasting conditions.
Results: Six comparisons were performed among the 4 treatments 
to investigate the bioequivalence of different gabapentin formula-
tions. In all comparisons, the 90% CIs for the reference/test ratio 
of Cmax, AUCt, and AUCinf were within the routine 80.00% to 
125.00% criterion. The safety and tolerability profiles were com-
parable.
Conclusion: In this comparative bioavailability study, all 3 generic 
formulations of gabapentin were found to be interchangeable with 
Neurontin® and were also shown to be bioequivalent to each 
other. These results indicate the absence of a “drifting” problem 
upon gabapentin generic–generic exchange. Our study results are 
in line with those obtained from a previously conducted simulation 
study with topiramate and gabapentin based on bioequivalence data 
present in the registration files of the Dutch Medicines Evaluation 
Board1. Compared with the simulation study for generic-generic 
interchange, the ratios in the currently reported comparative bio-
availability study are comparable, albeit with narrower 90% CIs 
for Cmax and AUCt.
Disclosure of Interest: None declared.
reference
1. Maliepaard M , Banishki N , Gispen-de Wied C C , et al. 
Interchangeability of generic anti-epileptic drugs: a quantitative 
analysis of topiramate and gabapentin. Eur J Clin Pharmacol. 
2011;67:1007–1016.
OC023—dO TreaTmeNT QualITy INdICaTOrS 
predICT CardIOVaSCular OuTCOmeS IN 
paTIeNTS WITh dIaBeTeS?
G. Sidorenkov*; J. Voorham; D. de Zeeuw;  
F.M. Haaijer-Ruskamp; and P. Denig
Clinical Pharmacology, University Medical Center Groningen, 
Groningen, the Netherlands
Introduction: Landmark clinical trials have led to optimal treatment 
recommendations for patients with diabetes. However, whether opti-
mal treatment is actually delivered in practice is more important than 
the efficacy of the drugs tested in trials. To this end, treatment qual-
ity indicators have been developed and tested against intermediate 
outcomes of cardiovascular complications. No studies have tested 
whether these treatment quality indicators also predict hard patient 
outcomes.
Patients (or Materials) and Methods: Data were collected from 
10,058 patients with diabetes in the Groningen Initiative to Analyze 
Type 2 Treatment (GIANTT) database and Dutch Hospital Data 
register. Included quality indicators measured glucose, lipid, blood 
pressure, and albuminuria-lowering treatment status and treatment 
intensification when indicated. Hard patient outcome was the com-
posite of cardiovascular events and all-cause death. Associations 
